	Changes in requirements from 2023 are highlighted in yellow.			
NAACCR Item #	NAACCR Item Name	Section	Comment	
10	Record Type	Record ID	System generated	
			System generated, required diagnosis year 2014 and	
21	Patient System ID-Hosp	Record ID	later. Not required for Abstract Plus users	
50	NAACCR Record Version	Record ID		
			System generated, required diagnosis year 2014 and	
60	Tumor Record Number	Record ID	later. Not required for Abstract Plus users	
70	Addr at DXCity	Demographic		
80	Addr at DXState	Demographic		
90	County at DX Reported	Demographic		
100	Addr at DXPostal Code	Demographic		
102	Addr at DXCountry	Demographic		
150	Marital Status at DX	Demographic		
160	Race 1	Demographic	Primary race code for all diagnosis years	
161	Race 2	Demographic	Diagnosis year 2000 and later	
	D 2			
162	Race 3	Demographic	Diagnosis year 2000 and later	
163	Race 4	Demographic	Diagnosis year 2000 and later	
164	Race 5	Demographic	Diagnosis year 2000 and later	
190	Spanish/Hispanic Origin	Demographic		
220	Sex	Demographic		
230	Age at Diagnosis	Demographic	Calculated from Date of Birth and Date of Diagnosis	
240	Date of Birth	Demographic		
252	BirthplaceState	Demographic		
254	BirthplaceCountry	Demographic		
234	Diffiplace Country	Бетовтартие	Diagnosis year 2022 and later, required when	
344	Tobacco Use Smoking Status	Demographic	available	
390	Date of Diagnosis	Cancer Identification		
400	Primary Site	Cancer Identification		
410	Laterality	Cancer Identification		
440	Grade	Cancer Identification	Required through diagnosis year 2017	
490	Diagnostic Confirmation	Cancer Identification		
500	Type of Reporting Source	Cancer Identification		
501	Casefinding Source	Cancer Identification	Diagnosis year 2006 and later	
522	Histologic Type ICD-O-3	Cancer Identification	Diagnosis year 2001 and later	
523	Behavior Code ICD-O-3	Cancer Identification	Diagnosis year 2001 and later	
540	Reporting Facility	Hospital-Specific	2227 11 1	
545	NPIReporting Facility	Hospital-Specific	Diagnosis year 2007 and later as available	
550	Accession NumberHosp	Hospital Specific	Not required for Abstract Plus users.	
560	Sequence NumberHospital	Hospital-Specific	For abstracts with Date Case Initiated 1/1/2014 and	
			later, the three-digit state assigned Abstractor ID	
570	Abstracted By	Hospital-Specific	must be used.	
580	Date of 1st Contact	Hospital-Specific		

	Changes in re	equirements from 2023 ar	re highlighted in yellow.
NAACCR			_
Item #	NAACCR Item Name	Section	Comment
610	Class of Case	Hospital-Specific	
630	Primary Payer at DX	Hospital-Specific	Diagnosis year 2006 and later
670	RX HospSurg Prim Site 03-2022	Hospital-Specific	Diagnosis year 2003 - 2022
671	RX HospSurg Prim Site 2023	Hospital-Specific	Diagnosis year 2023 and later
672	RX HospScope Reg LN Sur	Hospital-Specific	
674	RX HospSurg Oth Reg/Dis	Hospital-Specific	
	Date Regional Lymph Node		
682	Dissection	Stage/Prognostic Factors	Diagnosis year 2018 and later
700	RX HospChemo	Hospital-Specific	
710	RX HospHormone	Hospital-Specific	
720	RX HospBRM	Hospital-Specific	
730	RX HospOther	Hospital-Specific	
751	RX Hosp-Recon Breast	Hospital-Specific	Diagnosis year 2024 and later
752	Tumor Size Clinical	Stage/Prognostic Factors	Diagnosis year 2016 - 2023
754	Tumor Size Pathologic	Stage/Prognostic Factors	Diagnosis year 2016 - 2023
756	Tumor Size Summary	Stage/Prognostic Factors	Diagnosis year 2016 and later
759	SEER Summary Stage 2000	Stage/Prognostic Factors	Diagnosis year 2001-2003 and 2015-2017
764	Summary Stage 2018	Stage/Prognostic Factors	Diagnosis year 2018 and later
772	EOD Primary Tumor	Stage/Prognostic Factors	Diagnosis year 2018 and later
774	EOD Regional Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later
776	EOD Mets	Stage/Prognostic Factors	Diagnosis year 2018 and later
820	Regional Nodes Positive	Stage/Prognostic Factors	Diagnosis year 1999 and later
830	Regional Nodes Examined	Stage/Prognostic Factors	Diagnosis year 1999 and later
	Date of Sentinel Lymph Node		Diagnosis year 2018 and later, Required when
832	Biopsy	Stage/Prognostic Factors	available (Breast and Melanoma of Skin)
			Diagnosis year 2018 and later (Breast and Melanoma
834	Sentinel Lymph Nodes Examined	Stage/Prognostic Factors	of Skin)
			Diagnosis year 2018 and later (Breast and Melanoma
835	Sentinel Lymph Nodes Positive	Stage/Prognostic Factors	of Skin)
880	TNM Path T	Stage/Prognostic Factors	
890	TNM Path N	Stage/Prognostic Factors	AJCC TNM 7th Edition:
900	TNM Path M	Stage/Prognostic Factors	Diagnosis year 2015:
910	TNM Path Stage Group	Stage/Prognostic Factors	Required for CoC-accredited hospitals
920	TNM Path Descriptor	Stage/Prognostic Factors	Required, when available for other
930	TNM Path Staged By	Stage/Prognostic Factors	reporting facilities
940	TNM Clin T	Stage/Prognostic Factors	
950	TNM Clin N	Stage/Prognostic Factors	Diagnosis year 2016 and 2017:
960	TNM Clin M	Stage/Prognostic Factors	Required for all reporting facilities
970	TNM Clin Stage Group	Stage/Prognostic Factors	
980	TNM Clin Descriptor	Stage/Prognostic Factors	
990	TNM Clin Staged By	Stage/Prognostic Factors	—
1060	TNM Edition Number	Stage/Prognostic Factors	Diagnosis year 2016 and 2017
1068	Grade Post Therapy Clin (yc)	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
1112	Mets at DX-Bone	Stage/Prognostic Factors	Diagnosis year 2016 and later
1113	Mets at DX-Brain	Stage/Prognostic Factors	Diagnosis year 2016 and later
1114	Mets at Dx-Distant LN	Stage/Prognostic Factors	Diagnosis year 2016 and later

	Changes in re	quirements from 2023 are	highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
1115	Mets at DX-Liver	Stage/Prognostic Factors	Diagnosis year 2016 and later
1116	Mets at DX-Lung	Stage/Prognostic Factors	Diagnosis year 2016 and later
1117	Mets at DX-Other	Stage/Prognostic Factors	Diagnosis year 2016 and later
1182	Lymphovascular Invasion	Stage/Prognostic Factors	Diagnosis year 2010 and later
1200	RX Date Surgery	Treatment-1st Course	
1210	RX Date Radiation	Treatment-1st Course	
1220	RX Date Chemo	Treatment-1st Course	
1230	RX Date Hormone	Treatment-1st Course	
1240	RX Date BRM	Treatment-1st Course	
1250	RX Date Other	Treatment-1st Course	
1260	Date Initial RX SEER	Treatment-1st Course	
1270	Date 1st Crs RX CoC	Treatment-1st Course	
1285	RX SummTreatment Status	Treatment-1st Course	Diagnosis year 2010 and later
1290	RX SummSurg Prim Site 03-2022	Treatment-1st Course	Diagnosis year 2003 - 2022
1291	RX SummSurg Prim Site 2023	Treatment-1st Course	Diagnosis year 2023 and later
1292	RX SummScope Reg LN Sur	Treatment-1st Course	Diagnosis year 2003 and later
1294	RX SummSurg Oth Reg/Dis	Treatment-1st Course	Diagnosis year 2003 and later
1320	RX SummSurgical Margins	Treatment-1st Course	Required, when available
1335	RX SummRecon Breast	Treatment-1st Course	Diagnosis year 2024 and later
1340	Reason for No Surgery	Treatment-1st Course	Diagnosis year 2024 and later
1360	RX SummRadiation	Treatment-1st Course	Required through diagnosis year 2017
1380	RX SummSurg/Rad Seq	Treatment-1st Course	Required through diagnosis year 2017
1390	RX SummChemo	Treatment-1st Course	
1400	RX SummHormone	Treatment-1st Course	
1410	RX SummBRM	Treatment-1st Course	
1420	RX SummOther	Treatment-1st Course	
1430	Reason for No Radiation	Treatment-1st Course	
1501	Phase I Dose per Fraction	Treatment-1st Course	Required, when available
1	Phase I Radiation External Beam	Treatment 15t course	required, when available
1502	Planning Tech	Treatment-1st Course	Required, when available
1503	Phase I Number of Fractions	Treatment-1st Course	Required, when available
1	Phase I Radiation Primary	Treatment 15t course	required, when available
1504	Treatment Volume	Treatment-1st Course	Required, when available
130	Phase I Radiation to Draining	Treatment 13t course	nequires) when available
1505	Lymph Nodes	Treatment-1st Course	Required, when available
	Phase I Radiation Treatment		
1506	Modality	Treatment-1st Course	Required
1507	Phase I Total Dose	Treatment-1st Course	Required, when available
1511	Phase II Dose per Fraction	Treatment-1st Course	Required, when available
	Phase II Radiation External Beam		
1512	Planning Tech	Treatment-1st Course	Required, when available
1513	Phase II Number of Fractions	Treatment-1st Course	Required, when available
<u> </u>	Phase II Radiation Primary		<u> </u>
1514	Treatment Volume	Treatment-1st Course	Required, when available
	Phase II Radiation to Draining		
1515	Lymph Nodes	Treatment-1st Course	Required, when available

	Changes in re	quirements from 2023 are	highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name Phase II Radiation Treatment	Section	Comment
1516	Modality	Treatment-1st Course	Required
1517	Phase II Total Dose	Treatment-1st Course	Required, when available
1521	Phase III Dose per Fraction	Treatment-1st Course	Required, when available
1321	Phase III Radiation External Beam	Treatment-13t Course	Required, when available
1522	Planning Tech	Treatment-1st Course	Required, when available
1523	Phase III Number of Fractions	Treatment-1st Course	Required, when available
1323	Phase III Radiation Primary	Treatment 13t course	nequires, when available
1524	Treatment Volume	Treatment-1st Course	Required, when available
	Phase III Radiation to Draining		inequires, time i aranas e
1525	Lymph Nodes	Treatment-1st Course	Required, when available
	Phase III Radiation Treatment		-4
1526	Modality	Treatment-1st Course	Required
1527	Phase III Total Dose	Treatment-1st Course	Required, when available
	Radiation Treatment		
1531	Discontinued Early	Treatment-1st Course	Required, when available
	Number of Phases of Rad		
1532	Treatment to this Volume	Treatment-1st Course	Required, when available
1533	Total Dose	Treatment-1st Course	Required, when available
			Diagnosis year 2006-2011 all cases, 2012-2014 site-
1570	RadRegional RX Modality	Treatment-1st Course	specific, and 2015-2017 all cases
1632	Neoadjuvant Therapy	Treatment-1st Course	Diagnosis year 2021 and later
	Neoadjuvant Therapy-Clinical		
1633	Response	Treatment-1st Course	Diagnosis year 2021 and later
	Neoadjuvant Therapy-Treatment		
1634	Effect	Treatment-1st Course	Diagnosis year 2021 and later
1639	RX SummSystemic/Sur Seq	Treatment-1st Course	Diagnosis year 2006 and later
1750	Date of Last Contact	Follow-up/Recurrence/Death	
1760	Vital Status	Follow-up/Recurrence/Death	
			Diagnosis year 2022 and later, required when
1770	Cancer Status	Follow-up/Recurrence/Death	available
	Date of Last Cancer (tumor)		Diagnosis year 2022 and later, required when
1772	Status	Follow-up/Recurrence/Death	available
1810	Addr CurrentCity	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1820	Addr CurrentState	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1830	Addr CurrentPostal Code	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1832	Addr CurrentCountry	Demographic	Diagnosis year 2013 and later
1860	Recurrence Date1st	Follow-up/Recurrence/Death	Diagnosis year 2013 and later, required when available
			Diagnosis year 2013 and later, required when
1880	Recurrence Type1st	Follow-up/Recurrence/Death	available
1942	Place of DeathState	Demographic	Required, when available
1944	Place of DeathCountry	Demographic	Required, when available
1981-		Edit Overrides/ Conversion	
2078	Edit Over-ride Flags	History/ System Admin	
		Edit Overrides/ Conversion	
2085	Date Case Initiated	History/ System Admin	System generated

	Changes in r	equirements from 2023 are	e highlighted in yellow.
NAACCR	NAACCR Item Name	Section	Comment
Item #	NAACCK ITEIII Naiile	Edit Overrides/ Conversion	Comment
2110	Date Case Report Exported	History/ System Admin	System generated
2110	Date Case Report Exported	Edit Overrides/ Conversion	System generated
2117	Schema ID Version Current	History/ System Admin	System generated
,	Schema is version current	Edit Overrides/ Conversion	o jotem generatea
2118	Schema ID Version Original	History/ System Admin	System generated
		Edit Overrides/ Conversion	- Jane Branch
2152	CoC Accredited Flag	History/ System Admin	System generated
l İ	AJCC Cancer Surveillance DLL	Edit Overrides/ Conversion	, 0
2158	Version Current	History/ System Admin	System generated
	AJCC Cancer Surveillance DLL	Edit Overrides/ Conversion	
2159	Version Original	History/ System Admin	System generated
		Edit Overrides/ Conversion	
2170	Vendor Name	History/ System Admin	
2230	NameLast	Patient-Confidential	
2232	NameBirth Surname	Patient-Confidential	
2240	NameFirst	Patient-Confidential	
2250	NameMiddle	Patient-Confidential	
2270	NameSuffix	Patient-Confidential	
2280	NameAlias	Patient-Confidential	
2290	NameSpouse/Parent	Patient-Confidential	
2300	Medical Record Number	Patient-Confidential	
2320	Social Security Number	Patient-Confidential	
2330	Addr at DXNo & Street	Patient-Confidential	
2335	Addr at DXSupplementl	Patient-Confidential	
2350	Addr CurrentNo & Street	Patient-Confidential	Diagnosis year 2013 and later
2355	Addr CurrentSupplementl	Patient-Confidential	Diagnosis year 2013 and later
2360	Telephone	Patient-Confidential	
2415	NPIInst Referred From	Hospital-Confidential	Diagnosis year 2007 and later as available
2425	NPIInst Referred To	Hospital-Confidential	Diagnosis year 2007 and later as available
2460	PhysicianManaging	Other-Confidential	The NPI is the preferred ID number for collection. If
2465	NPIPhysicianManaging	Other-Confidential	NPIPhysicianManaging is blank, Physician Managing cannot be blank.
	, ,		The NPI is the preferred ID number for collection. If
2470	PhysicianFollow-Up	Other-Confidential	NPIPhysicianFollow-Up is blank, PhysicianFollow
2475	NPIPhysicianFollow-Up	Other-Confidential	up cannot be blank.
2480	PhysicianPrimary Surg	Other-Confidential	The NPI is the preferred ID number for collection.If NPIPhysicianPrimary Surg is blank, PhysicianPrimary Surg cannot be blank. Exception : if surgery
2485	NPIPhysicianPrimary Surg	Other-Confidential	of primary site codes indicate surgery was not done, NPIPhysicianPrimary Surg and PhysicianPrimary Surg may both be blank.
			The NPI is the preferred ID number for collection.
2490	Physician 3	Other-Confidential	NPIPhysician 3 or Physician 3 are Required, when
2495	NPIPhysician 3	Other-Confidential	available.
2500	Physician 4	Other-Confidential	The NPI is the preferred ID number for collection. NPIPhysician 4 or Physician 4 are Required, when
2505	NPIPhysician 4	Other-Confidential	available.

	Changes in re	equirements from 2023 are h	nighlighted in yellow.
NAACCR Item #	NAACCR Item Name	Section	Comment
2520	TextDX ProcPE	Text-Diagnosis	
2530	TextDX ProcX-ray/Scan	Text-Diagnosis	
2540	TextDX ProcScopes	Text-Diagnosis	1
2550	TextDX ProcLab Tests	Text-Diagnosis	1
2560	TextDX ProcOp	Text-Diagnosis	
2570	TextDX ProcPath	Text-Diagnosis	
2580	TextPrimary Site Title	Text-Diagnosis	
2590	TextHistology Title	Text-Diagnosis	There MUST be text to support coding of data fields
2600	TextStaging	Text-Diagnosis	in the cancer identification, stage and treatment sections of the abstract.
2610	RX TextSurgery	Text-Treatment	
2620	RX TextRadiation (Beam)	Text-Treatment	
2630	RX TextRadiation Other	Text-Treatment	
2640	RX TextChemo	Text-Treatment	
2650	RX TextHormone	Text-Treatment	
2660	RX TextBRM	Text-Treatment	
2670	RX TextOther	Text-Treatment	
2680	TextRemarks	Text-Miscellaneous	Additional text or overflow from other text fields
2690	TextPlace of Diagnosis	Text-Miscellaneous	Text about facility, physician office, city, state, or county where the diagnosis was made.
2800	CS Tumor Size	Stage/Prognostic Factors	Diagnosis year 2004-2017
2810	CS Extension	Stage/Prognostic Factors	Diagnosis year 2004-2017
2820	CS Tumor Size/Ext Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017
2830	CS Lymph Nodes	Stage/Prognostic Factors	Diagnosis year 2004-2017
2840	CS Lymph Nodes Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017
2850	CS Mets at DX	Stage/Prognostic Factors	Diagnosis year 2004-2017
2851	CS Mets at DX-Bone	Stage/Prognostic Factors	Diagnosis year 2010-2015
2852	CS Mets at DX-Brain	Stage/Prognostic Factors	Diagnosis year 2010-2015
2853	CS Mets at DX-Liver	Stage/Prognostic Factors	Diagnosis year 2010-2015
2854	CS Mets at DX-Lung	Stage/Prognostic Factors	Diagnosis year 2010-2015
2860	CS Mets Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017
2861	CS Site-Specific Factor 7	Stage/Prognostic Factors	
2862	CS Site-Specific Factor 8	Stage/Prognostic Factors	
2863	CS Site-Specific Factor 9	Stage/Prognostic Factors	
2864	CS Site-Specific Factor10	Stage/Prognostic Factors	

	Changes in r	equirements from 2023 a	re highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
2865	CS Site-Specific Factor11	Stage/Prognostic Factors	
2866	CS Site-Specific Factor12	Stage/Prognostic Factors	
2867	CS Site-Specific Factor13	Stage/Prognostic Factors	Diagnosis year 2004-2017
2868	CS Site-Specific Factor14	Stage/Prognostic Factors	For CS Site-Specific Factor
2869	CS Site-Specific Factor15	Stage/Prognostic Factors	coding requirements, see the
2870	CS Site-Specific Factor16	Stage/Prognostic Factors	NCI-SEER website:
2871	CS Site-Specific Factor17	Stage/Prognostic Factors	
2872	CS Site-Specific Factor18	Stage/Prognostic Factors	
2873	CS Site-Specific Factor19	Stage/Prognostic Factors	Required Factors
2874	CS Site-Specific Factor20	Stage/Prognostic Factors	SEER, Version 0205
2875	CS Site-Specific Factor21	Stage/Prognostic Factors	
2876	CS Site-Specific Factor22	Stage/Prognostic Factors	
2877	CS Site-Specific Factor23	Stage/Prognostic Factors	
2878	CS Site-Specific Factor24	Stage/Prognostic Factors	http://seer.cancer.gov/csreqstatus/application.html
2879	CS Site-Specific Factor25	Stage/Prognostic Factors	?report=requiredFactors&setter=seer&version=0205
2880	CS Site-Specific Factor 1	Stage/Prognostic Factors	&schema=0&years=0
2890	CS Site-Specific Factor 2	Stage/Prognostic Factors	
2900	CS Site-Specific Factor 3	Stage/Prognostic Factors	
2910	CS Site-Specific Factor 4	Stage/Prognostic Factors	
2920	CS Site-Specific Factor 5	Stage/Prognostic Factors	
2930	CS Site-Specific Factor 6	Stage/Prognostic Factors	
2935	CS Version Input Original	Stage/Prognostic Factors	Diagnosis year 2004-2017
2936	CS Version Derived	Stage/Prognostic Factors	Diagnosis year 2004-2017
2937	CS Version Input Current	Stage/Prognostic Factors	Diagnosis year 2004-2017
2940	Derived AJCC-6 T	Stage/Prognostic Factors	Diagnosis year 2004-2017
2950	Derived AJCC-6 T Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
2960	Derived AJCC-6 N	Stage/Prognostic Factors	Diagnosis year 2004-2017
2970	Derived AJCC-6 N Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
2980	Derived AJCC-6 M	Stage/Prognostic Factors	Diagnosis year 2004-2017
2990	Derived AJCC-6 M Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
3000	Derived AJCC-6 Stage Grp	Stage/Prognostic Factors	Diagnosis year 2004-2017
3010	Derived SS1977	Stage/Prognostic Factors	Diagnosis year 2004-2017
3020	Derived SS2000	Stage/Prognostic Factors	Diagnosis year 2004-2017
3030	Derived AJCCFlag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3040	Derived SS1977Flag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3050	Derived SS2000Flag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3170	RX Date Mst Defn Srg	Treatment-1st Course	Diagnosis year 2015 and later
3230	RX Date Systemic	Treatment-1st Course	
3250	RX SummTransplnt/Endocr	Treatment-1st Course	
3400	Derived AJCC-7 T	Stage/Prognostic Factors	Diagnosis year 2010-2017
3402	Derived AJCC-7 T Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017
3410	Derived AJCC-7 N	Stage/Prognostic Factors	Diagnosis year 2010-2017
3412	Derived AJCC-7 N Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017
3420	Derived AJCC-7 M	Stage/Prognostic Factors	Diagnosis year 2010-2017
3422	Derived AJCC-7 M Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017
3430	Derived AJCC-7 Stage Grp	Stage/Prognostic Factors	Diagnosis year 2010-2017
-		- 1000, 951103610 1 000013	Diagnosis year 2018 and later schema-specific

	Changes in re	quirements from 2023 ar	re highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
3780-			
3798	Secondary Diagnosis 1-10	Stage/Prognostic Factors	Required, when available
3800	Schema ID	Stage/Prognostic Factors	System generated
	Chromosome 1p: Loss of		
3801	Heterozygosity (LOH)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Chromosome 19q: Loss of	<u>.</u>	2010 1111 151
3802	Heterozygosity (LOH)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2222	Adoptid Custic Decalaid Dettern	5. /5	Diagnasia yang 2010 and latan sahama anasifia
3803	Adenoid Cystic Basaloid Pattern	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3804	Adenopathy	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2005	AED Dost Orshipstomy Lab Value	C+/D	Diagnosis year 2019 and later schema specific
3805	AFP Post-Orchiectomy Lab Value AFP Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3806	AFP Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2007	AFP Pre-Orchiectomy Lab Value	Stage/Drognestic Factors	Diagnosis year 2018 and later schema-specific
3807	AFP Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3808	AFF FIE-Ordinectomy Name	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3809	AFP Pretreatment Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3810	AFP Pretreatment Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3811	Anemia	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3812	B symptoms	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3012	Bilirubin Pretreatment Total Lab	Stage/Flogilostic Factors	Diagnosis year 2010 and later schema specific
3813	Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3013	Bilirubin Pretreatment Unit of	Stage/110ghostic 1 detois	
3814	Measure	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3815	Bone Invasion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3816	Brain Molecular Markers	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3817	Breslow Tumor Thickness	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3017	CA-125 Pretreatment	Stage, Fragmostic Factors	
3818	Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3819	CEA Pretreatment Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3820	CEA Pretreatment Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3821	Chromosome 3 Status	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3822	Chromosome 8q Status	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Circumferential Resection Margin	0.0	
3823	(CRM)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Creatinine Pretreatment Lab		
3824	Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Creatinine Pretreatment Unit of		
3825	Measure	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Estrogen Receptor Percent		
3826	Positive or Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3827	Estrogen Receptor Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Estrogen Receptor Total Allred		
3828	Score	Stage/Prognostic Factors	Diagnosis year 2018 - 2022 schema-specific
	Esophagus and EGJ Tumor		
3829	Epicenter	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific

	Changes in re	quirements from 2023 ar	e highlighted in yellow.
NAACCR Item #	NAACCR Item Name	Section	Comment
iteiii #	Extranodal Extension Clin (non-		
3830	Head and Neck)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Extranodal Extension Head and		
3831	Neck Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Extranodal Extension Head and		
3832	Neck Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Extranodal Extension Path (non-		
3833	Head and Neck)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3834	Extravascular Matrix Patterns	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3835	Fibrosis Score	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3836	FIGO Stage	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Gestational Trophoblastic		
3837	Prognostic Scoring Index	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3838	Gleason Patterns Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3839	Gleason Patterns Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3840	Gleason Score Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3841	Gleason Score Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3842	Gleason Tertiary Pattern	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3843	Grade Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later
3844	Grade Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later
3845	Grade Post Therapy Path (yp)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	h CC Dark Onahia atama dah Malaa		Diamania wasa 2010 ay dilatay ada ay a safiis
3846	hCG Post-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3847	hCG Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3848	hCG Pre-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3849	hCG Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3850	HER2 IHC Summary	Stage/Prognostic Factors	Diagnosis year 2019-2020 schema-specific
	HER2 ISH Dual Probe Copy		
3851	Number	Stage/Prognostic Factors	Diagnosis year 2019-2020 schema-specific
3852	HER2 ISH Dual Probe Ratio	Stage/Prognostic Factors	Diagnosis year 2019-2020 schema-specific
	HER2 ISH Single Probe Copy		
3853	Number	Stage/Prognostic Factors	Diagnosis year 2019-2020 schema-specific
3854	HER2 ISH Summary	Stage/Prognostic Factors	Diagnosis year 2019-2020 schema-specific
3855	HER2 Overall Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3856	Heritable Trait	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3857	High Risk Cytogenetics	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3858	High Risk Histologic Features	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3859	HIV Status	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	International Normalized Ratio		
3860	Prothrombin Time	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Ipsilateral Adrenal Gland		
3861	Involvement	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3862	JAK2	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3863	Ki-67	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3864	Invasion Beyond Capsule	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3865	KIT Gene Immunohistochemistry	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific

	Changes in re	quirements from 2023 ar	re highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
3866	KRAS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3867	LDH Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3868	LDH Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3869	LDH Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3870	LDH Upper Limits of Normal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	LN Assessment Method Femoral-		
3871	Inguinal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	LN Assessment Method Para-		
3872	Aortic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3873	LN Assessment Method Pelvic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3874	LN Distant Assessment Method	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3875	LN Distant: Mediastinal Scalene	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3876	LN Head and Neck Levels I-III	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3877	LN Head and Neck Levels IV-V	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3878	LN Head and Neck Levels VI-VII	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3879	LN Head and Neck Other	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3880	LN Isolated Tumor Cells (ITC)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3881	LN Laterality	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3882	LN Positive Axillary Level I-II	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3883	LN Size	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3885	Lymphocytosis	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3886	Major Vein Involvement	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3887	Measured Basal Diameter	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3888	Measured Thickness	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Methylation of O6-Methylguanine		
2000	Methyltransferase		Diagnosis year 2018 and later schema-specific
3889	·	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3890	Microsatellite Instability (MSI) Microvascular Density	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific Diagnosis year 2018 and later schema-specific
3891	IVIICTOVASCUIAT DETISITY	Stage/Prognostic Factors	Diagnosis year 2016 and later schema-specific
3892	Mitotic Count Uveal Melanoma	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3893	Mitotic Rate Melanoma	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3894	Multigene Signature Method	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3895	Multigene Signature Results	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
İ	NCCN International Prognostic	3. 0	
3896	Index (IPI)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3897	Number of Cores Examined	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3898	Number of Cores Positive	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Examined Para-Aortic		
3899	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Examined Pelvic		
3900	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Positive Para-Aortic		
3901	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3902	Number of Positive Pelvic Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific

NIAACCE	Changes in requirements from 2023 are highlighted in yellow.			
NAACCR Item #	NAACCR Item Name	Section	Comment	
	Oncotype Dx Recurrence Score-	5. /5 5	Diagraphic was 2010 and later selection and sitis	
3903	DCIS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Oncotype Dx Recurrence Score-		Diagnasia wasa 2010 and later ashama an asifia	
3904	Invasive	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3905	Oncotype Dx Risk Level-DCIS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3906	Oncotype Dx Risk Level-Invasive	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3907	Organomegaly	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Percent Necrosis Post			
3908	Neoadjuvant	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3909	Perineural Invasion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
910	Peripheral Blood Involvement	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
8911	Peritoneal Cytology	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3913	Pleural Effusion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Progesterone Receptor Percent	5, 5	·	
3914	Positive or Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3915	Progesterone Receptor Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Progesterone Receptor Total			
3916	Allred Score	Stage/Prognostic Factors	Diagnosis year 2018 - 2022 schema-specific	
917	Primary Sclerosing Cholangitis	Stage/Prognostic Factors	Diagnosis year 2018 - 2021 schema-specific	
3918	Profound Immune Suppression	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	EOD Prostate Pathologic			
3919	Extension	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	PSA (Prostatic Specific Antigen)			
3920	Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Residual Tumor Volume Post			
3921	Cytoreduction	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Response to Neoadjuvant			
3922	Therapy	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
923	S Category Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
924	S Category Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3925	Sarcomatoid Features	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
926	Schema Discriminator 1	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
927	Schema Discriminator 2	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
928	Schema Discriminator 3	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3929	Separate Tumor Nodules	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Serum Albumin Pretreatment			
930	Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Serum Beta-2 Microglobulin			
931	Pretreatment Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
932	LDH Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
933	Thrombocytopenia	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3934	Tumor Deposits	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
935	Tumor Growth Pattern	Stage/Prognostic Factors	Diagnosis year 2018 - 2021 schema-specific	
936	Ulceration	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
	Visceral and Parietal Pleural			
	l.	C. /D .: F .	Diagnosis year 2018 and later schema-specific	
3937	Invasion	Stage/Prognostic Factors	Diagnosis year 2016 and later schema-specific	

	Changes in requirements from 2023 are highlighted in yellow.			
NAACCR Item #	NAACCR Item Name	Section	Comment	
3939	EGFR Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3940	BRAF Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3941	NRAS Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3942	CA 19-9 PreTX Lab Value	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3943	NCDBSARSCoV2Test	Special Use	Required when available through diagnosis year 2022	
3944	NCDBSARSCoV2Pos	Special Use	Required when available through diagnosis year 2022	
3945	NCDBSARSCoV2Pos Date	Special Use	Required when available through diagnosis year 2022	
3946	NCDBCOVID19Tx Impact	Special Use	Required when available through diagnosis year 2022	
3950	Macroscopic Evaluation of Mesorectum	Stage/Prognostic Factors	Diagnosis year 2022 and later schema-specific	
3956	p16	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3957	LN Status Pelvic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3958	LN Status Para-Aortic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3959	LN Status Femoral-Inguinal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3960	Histologic Subtype	Stage/Prognostic Factors	Diagnosis year 2023 and later schema-specific	
3961	Clinical Margin Width	Stage/Prognostic Factors	Diagnosis year 2023 and later schema-specific	
3964	Brain Primary Tumor Location	Stage/Prognostic Factors	Diagnosis year 2024 and later schema-specific	
7090	Path Report Number 1	Pathology	Required, when available	

In addition to the data items specified in the required data set, Georgia accepts and would like to receive all data items collected by CoC-accredited programs in our state as part of regular monthly submissions.